vs
Side-by-side financial comparison of MVB FINANCIAL CORP (MVBF) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $36.7M, roughly 1.6× MVB FINANCIAL CORP). MVB FINANCIAL CORP runs the higher net margin — 0.0% vs -92.6%, a 92.6% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 2.8%).
MVB Financial Corp is a U.S.-based financial holding company offering commercial and retail banking services, wealth management, mortgage lending, and deposit products. It also provides specialized digital banking solutions for fintech and gaming enterprises, primarily serving customers across the U.S. Mid-Atlantic region.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MVBF vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $36.7M | $60.1M |
| Net Profit | $0 | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | — | -87.1% |
| Net Margin | 0.0% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.39 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $36.7M | $60.1M | ||
| Q4 25 | $39.1M | $57.3M | ||
| Q3 25 | $61.2M | $51.3M | ||
| Q2 25 | $33.7M | $48.5M | ||
| Q1 25 | $33.7M | $32.7M | ||
| Q4 24 | $46.2M | $41.8M | ||
| Q3 24 | $33.2M | $33.3M | ||
| Q2 24 | $34.7M | $29.1M |
| Q1 26 | $0 | $-55.6M | ||
| Q4 25 | $4.2M | $-47.5M | ||
| Q3 25 | $17.1M | $-52.9M | ||
| Q2 25 | $2.0M | $-46.6M | ||
| Q1 25 | $3.6M | $-49.5M | ||
| Q4 24 | $9.4M | $-43.3M | ||
| Q3 24 | $2.1M | $-43.6M | ||
| Q2 24 | $4.1M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 13.9% | -82.2% | ||
| Q3 25 | 38.3% | -102.6% | ||
| Q2 25 | 9.4% | -93.4% | ||
| Q1 25 | 14.3% | -143.7% | ||
| Q4 24 | 26.5% | -98.6% | ||
| Q3 24 | 8.4% | -132.0% | ||
| Q2 24 | 15.9% | -139.2% |
| Q1 26 | 0.0% | -92.6% | ||
| Q4 25 | 10.8% | -83.0% | ||
| Q3 25 | 28.0% | -103.1% | ||
| Q2 25 | 5.9% | -96.1% | ||
| Q1 25 | 10.6% | -151.4% | ||
| Q4 24 | 20.4% | -103.6% | ||
| Q3 24 | 6.3% | -131.2% | ||
| Q2 24 | 11.8% | -110.9% |
| Q1 26 | $0.39 | $-0.83 | ||
| Q4 25 | $0.32 | $-0.73 | ||
| Q3 25 | $1.32 | $-0.82 | ||
| Q2 25 | $0.15 | $-0.75 | ||
| Q1 25 | $0.27 | $-0.81 | ||
| Q4 24 | $0.72 | $-0.71 | ||
| Q3 24 | $0.16 | $-0.73 | ||
| Q2 24 | $0.31 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $334.9M | $122.9M |
| Total Assets | $3.3B | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $177.6M | $340.6M | ||
| Q4 25 | $244.1M | $388.9M | ||
| Q3 25 | $300.0M | $416.1M | ||
| Q2 25 | $399.4M | $291.0M | ||
| Q1 25 | $251.4M | $314.5M | ||
| Q4 24 | $317.9M | $320.6M | ||
| Q3 24 | $610.9M | $298.4M | ||
| Q2 24 | $455.5M | $319.1M |
| Q1 26 | $334.9M | $122.9M | ||
| Q4 25 | $334.0M | $139.1M | ||
| Q3 25 | $327.8M | $148.8M | ||
| Q2 25 | $302.3M | $-11.9M | ||
| Q1 25 | $310.1M | $18.9M | ||
| Q4 24 | $305.7M | $21.7M | ||
| Q3 24 | $303.1M | $11.2M | ||
| Q2 24 | $296.6M | $39.3M |
| Q1 26 | $3.3B | $442.3M | ||
| Q4 25 | $3.3B | $480.2M | ||
| Q3 25 | $3.2B | $506.9M | ||
| Q2 25 | $3.2B | $372.7M | ||
| Q1 25 | $3.0B | $386.7M | ||
| Q4 24 | $3.1B | $392.3M | ||
| Q3 24 | $3.4B | $363.6M | ||
| Q2 24 | $3.3B | $381.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MVBF
| Net Interest Income | $28.5M | 78% |
| Noninterest Income | $8.2M | 22% |
RYTM
Segment breakdown not available.
